Enbridge Inc.

Enbridge Inc. (NYSE: ENB) is an energy infrastructure company with business platforms that include a network of crude oil, liquids and natural gas pipelines, regulated natural gas distribution utilities and renewable power generation.

Key Highlights:

• Increasing uncertainties over oil demand amid resurging cases of Delta variant.
• Heightened transportation costs could create pressure on the margin profile of the company.
• Despite ENB shares are hovering near 52W High, the Average Directional Index (ADI) is indicating lack of strength in the recent uptrend as it is hovering below 20.
• Further, 14-day RSI is falling and hovering in a neutral zone with bearish bias.

Conclusion: Despite ENB is fundamentally strong company, with industry leading margin profile and balance sheet strength. The overall oil industry has become quite volatile on the back of resurgence in Delta variant cases in China and Western economies, which is throwing a lot of uncertainties over near-term oil demand. Further, technical indicators are sideways. Therefore, we recommend a “Watch” rating on the stock at the closing price of USD 39.21 on August 16, 2021 until a clear trend emerge out from this sideways trend.

Source: REFINITIV, Analysis by Kalkine Group

Fisker Inc

Fisker Inc. (NYSE: FSR), formerly Spartan Energy Acquisition Corp., is an automotive company. The Company designs and manufactures electric vehicles.

Key Highlights

• Negative Operating margin, EBITDA margin and Net Margin.
• MACD oscillator registered a crossover, where MACD oscillator moved below the 9-day SMA signal line.
• Negative Spread between 12-day and 26-day EMA
• 14-day RSI falling and indicating a bearish move from the current trading levels.

Conclusion: Shares of FSR are hovering in a bearish territory, and at the last closing, its shares traded below the crucial short-term as well as long-term moving averages of 200-day and 50-day SMAs. Further, on the last trading day, the leading momentum indicator, the Moving Average Convergence Divergence (MACD) moved below the 9-day SMA signal line and spread between 12-day and 26-day EMAs is negative, another bearish trend. Therefore, we recommend an “Avoid” rating at the stock at the closing price of USD 14.13 on August 16, 2021.

Source: REFINITIV, Analysis by Kalkine Group

Dare Bioscience, Inc

Dare Bioscience, Inc. (NASDAQ – DARE) is a clinical-stage biopharmaceutical company. The Company is focused on advancing products for women’s health.

Key Highlights:

• Submitted New Drug Application for DARE-BV1, a potential new first-line treatment for bacterial vaginosis, to the FDA in June, which received Priority Review with a PDUFA target date of December 7, 2021.
• Commenced the Phase 2b RESPOND study of Sildenafil Cream, 3.6%, a potential first-in-category product in development to treat female sexual arousal disorder, a physiological condition for which there are no FDA approved products.
• The company is yet to receive any approval from FDA. Any negative outcome from the FDA review would affect the business prospects.
• The company is in early stage and yet to generate revenue.
• Losses expanded in the June quarter of 2021 at Operating level and bottom-line losses also soared up.
• Stock Moved below the 200-day, and 50-day SMAs, which is a bearish indicator.
• 14-day RSI falling and hovering in a neutral zone with bearish bias at 46.
• MACD oscillator could move below the 9-day SMA signal line in next few trading session, as MACD is falling.

Conclusion: The company sales has not yet started, despite that its shares are already up approximately 33.3% in a year over period. Further, technical have turned bearish with its shares on the last trading session moved below the crucial short-term as well as long-term supports levels and charted into a long-term bearish zone. Hence, we recommend an “Avoid” rating on the stock at the closing price of USD 1.52 on August 16, 2021.

Source: REFINITIV, Analysis by Kalkine Group

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.